Session 20
Stem cell systems and 3D technologies: Implementation for in vitro liver toxicology assessment
Programme of the Session
- S20-01
Applying 3D-systems to toxicological assessment: Bridging academic research and industry needs
Laura Suter-Dick
Institute for Chemistry and Bioanalytics, School of Life Sciences (FHNW), Muttenz, Switzerland - S20-02
Improving hepatocyte-like cells (HLCs) derived from hnMSC for Toxicology applications using 3D culture systems
Joana P. Miranda
Department of Toxicological and Bromatological Sciences, Faculty of Pharmacy / Research Institute for Medicines, University of Lisbon, Lisbon, Portugal - S20-03
Stem cell derived hepatocyte like cells and primary human hepatocytes in relation to the in vivo situation
Jan G. Hengstler
Ifado, Dortmund, Germany - S20-04
Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury
Chris Goldring
MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, United Kingdom - S20-05
Characterization and application of iPSCs in drug discovery research. Focus in hepatocytes
Franziska Boess
Pharmaceutical Sciences, Hoffmann - La Roche, Basel, Switzerland - S20-06
Human induced pluripotent stem cells in hepatic toxicity assessment using 3D culture technologies - a StemBANCC approach
Katrin Zeilinger1, Nora Freyer1, Georg Damm2, Daniel Seehofer2, Frank Jacobs3, Fanny Knöspel1
1Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany; 2Department of Hepatobiliary Surgery and Visceral Transplantation, University of Leipzig, Leipzig, Germany; 3Janssen Pharmaceutica, Beerse, Belgium
Session Abstract
Industrial sectors, perform toxicological assessments of their potential products in order to ensure human safety and to fulfil regulatory requirements. Stem cell systems provide cell culture models that can be maintained in 2D- and 3D-cultures, can recapitulate many aspects of physiology and are amenable to a variety of toxicity assays. Stem cell derived systems from toxicity target organs such as the liver, heart and kidney, as well as keratinocytes and neurons have been generated in several laboratories. Their implementation in toxicity assessment in the industrial setting depends on the scientific and technological advances as well as on the practical challenges that need to be overcome. Some of those challenges are (i) the generation of a high number of cells and (ii) the maintenance of a mature differentiated phenotypes, and (iii) applicability in an industrial and regulatory setting.
This workshop will attempt to focus the recent development in this field, namely on the use of 3D cultures as alternative in vitro models, with a focus on hepatotoxicity. The list of speakers includes academic and industrial (Pharma) scientists that are recognized as experts in the field of stem cell research and their implementation in drug discovery.
